---
title: "Goldman Sachs lowers UNITED LAB sales and profit forecasts, target price raised to 16.07 yuan"
description: "Goldman Sachs lowered UNITED LAB's sales forecast for 2023 to 2027 by 17.7% to 17.8%, and profit forecast by 28.4% to 35.6%. It is expected that the prices of active pharmaceutical ingredients for ant"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255710490.md"
published_at: "2025-09-03T03:50:30.000Z"
---

# Goldman Sachs lowers UNITED LAB sales and profit forecasts, target price raised to 16.07 yuan

> Goldman Sachs lowered UNITED LAB's sales forecast for 2023 to 2027 by 17.7% to 17.8%, and profit forecast by 28.4% to 35.6%. It is expected that the prices of active pharmaceutical ingredients for antibiotics will be weak in the next two years, but the sales forecast for insulin products has been raised by 27% to 30%. The target price has been raised from 15.29 yuan to 16.07 yuan, with a rating of "Neutral." Sales in the first half of the year increased by 5% year-on-year to 7.5 billion yuan, while core business revenue decreased by 15% year-on-year to 6.1 billion yuan, which was below expectations, and profit increased by 27% year-on-year to 1.9 billion yuan

Goldman Sachs lowered the sales forecast for UNITED LAB (03933.HK) for this year to 2027 by 17.7% to 17.8%, and the profit forecast was cut by 28.4% to 35.6%. It is expected that the price cycle for active pharmaceutical ingredients for antibiotics will be weak in the next two years, while the sales forecast for high-margin insulin products has been raised by 27% to 30%, benefiting from incremental sales brought by exports.

The firm raised its target price for the stock from HKD 15.29 to HKD 16.07, maintaining a "Neutral" rating. The firm indicated that the company's sales in the first half of the year increased by 5% year-on-year to RMB 7.5 billion, while core business revenue fell by 15% year-on-year to RMB 6.1 billion, which was below the firm's expectation of RMB 6.5 billion. Profit increased by 27% year-on-year to RMB 1.9 billion, but core profit declined and was below the firm's expectations. The firm noted that the gross margin of intermediates and bulk pharmaceuticals was eroded, and increased administrative expenses due to business expansion consulting fees

### Related Stocks

- [03933.HK - UNITED LAB](https://longbridge.com/en/quote/03933.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美团：本集团预期 2025 年度录得亏损约人民币 233 亿元至人民币 243 亿元 | 美团预计 2025 年度将录得亏损约人民币 233 亿元至 243 亿元，而 2024 年度则录得溢利约 358.08 亿元。预期亏损主要源于核心本地商业分部的经营溢利从 2024 年的约 524.15 亿元转为 2025 年的约 68 亿 | [Link](https://longbridge.com/en/news/275897016.md) |
| 民主党阻止拨款法案通过 美国土安全部面临停摆 | 美国参议院民主党人投票阻止一项为国土安全部提供资金的拨款法案，导致该部门面临停摆。投票结果为 52 票赞成、47 票反对，未能达到推进法案所需的 60 票。停摆将影响多个关键机构，包括联邦紧急事务管理局和运输安全管理局。参议院共和党计划提出 | [Link](https://longbridge.com/en/news/275824701.md) |
| 斯瓦尔巴群岛，下一个北极区域热点？ | 斯瓦尔巴群岛因其特殊的地理位置和丰富的资源，正面临国际关注。美国对格陵兰岛的兴趣引发了对斯瓦尔巴群岛的担忧，挪威外交部官员指出，格陵兰的政治动荡可能影响斯瓦尔巴群岛。该群岛是气候变化研究的中心，历史上曾是无主地，1920 年后归挪威主权，但 | [Link](https://longbridge.com/en/news/275529690.md) |
| 特朗普会以总理，称同伊朗达成协议将是 “首选” | 以美领导人讨论应对美伊谈判失败的 “共同行动方案”。特朗普表示，他已告知内塔尼亚胡，如果能够达成协议，这将是他们的首选方案；若无法达成协议，他们只能拭目以待。以总理被曝向特朗普提要求：与伊朗的协议不应设置到期时间。伊朗外长重申就和平核计划达 | [Link](https://longbridge.com/en/news/275665871.md) |
| AI 债务泡沫初现端倪？分析师警告：Alphabet 发行百年期债券或为市场 “见顶” 信号 | Alphabet 首次发行 10 亿英镑百年期债券，策略师警示，在信贷利差历史低位、AI 需求不确定及技术变革加速背景下，此举是市场过度乐观及 AI 泡沫积聚的典型信号。本次发行是其 200 亿美元多币种融资计划一部分。 | [Link](https://longbridge.com/en/news/275752138.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.